Andropause syndrome in men treated for metastatic prostate cancer: A qualitative study of the impact of symptoms

Cancer Nursing

Volumn 35, Issue 1, 2012, Pages 63-69

  Grunfeld, Elizabeth A ^a   Halliday, Amber ^a   Martin, Pauline ^b   Drudge Coates, Lawrence ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation; Andropause; Framework analysis; Hot flashes; Oncology; Prostate cancer; Qualitative research; Therapy

Indexed keywords

DIETHYLSTILBESTROL; GOSERELIN;

AGED; ANDROGEN DEPRIVATION THERAPY; ANDROPAUSE; ANDROPAUSE RELATED DISORDER; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; METASTASIS; NIGHT SWEAT; PRIORITY JOURNAL; PROSTATE CANCER; SEXUAL DYSFUNCTION;

ADAPTATION, PSYCHOLOGICAL; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROPAUSE; ANTINEOPLASTIC AGENTS, HORMONAL; COGNITION DISORDERS; GYNECOMASTIA; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITATIVE RESEARCH; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SWEATING; TREATMENT OUTCOME;

EID: 84857032479     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0b013e318211fa92     Document Type: Article

References (41)

1. Office for National Statistics, Cancer Statistics registrations: Registrations of Cancer Diagnosed in 2007, England Series MB1 no.38. London: National Statistics; 2010.
2. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009;10:351-369.
3. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
4. BollaM,Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360: 103-106.
5. Vis AN, SchrPder FH. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009; 104:438-448.
6. Soloway MS, Chodak G, Vogelzang MJ, et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. The Zoladex Prostate Study Group. Urology. 1991;37:46-51.
7. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-2575.
8. Gomella LG, Johannes J, Trabulsi EJ. Current prostate cancer treatments: effect on quality of life. Urology. 2009;73:S28-S35.
9. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist. 2003;8:474-487. (Pubitemid 37238876)
10. Drudge-Coates L. Bone health: the effect of androgen deprivation therapy in prostate cancer patients. Int J Urol Nurs. 2007;1:18-26.
11. Drudge-Coates L, Roberts J, Thompson PM. Gynaecomastia: a case study review of the effect of hormone therapy in the management of prostate cancer. Int J Urol Nurs. 2008;2:134-139.
12. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol. 2001;19:72-80. (Pubitemid 32063481)
13. Spetz AC, Zetterlund EL, Varenhorst E, Hammar M. Incidence and management of hot flashes in prostate cancer. J Support Oncol. 2003;1: 263-266.
14. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. Urol. 1992;147:956-961.
15. Spetz AC, Hammar M. Lindberg B. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001;166:517-520. (Pubitemid 32652235)
16. Nishiyama T, Kanazawa S. Watanabe R. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004;11:735-741. (Pubitemid 39387520)
17. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage. 1998;16: 327-333. (Pubitemid 28545914)
18. Hunter MS, Coventry S, Mendes N, Grunfeld EA. Menopausal symptoms following breast cancer treatment: a qualitative investigation of cognitive and behavioural responses. Maturitas. 2009a;63:336-340.
19. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994;52:1170-1173. (Pubitemid 24283460)
20. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Exp Opin Pharmacother. 2005;6:1095-1106. (Pubitemid 40959473)
21. Kattan MW. Measuring hot flashes in men treated with hormone ablation therapy; an unmet need. Urol Nurs. 2006;26:1-17.
22. Ritchie J, Spencer L, O'Connor W. Carrying out qualitative analysis. In: Ritchie J, Lewis J, eds. Qualitative Research Practice; A Guide for Social Science Students and Researchers. London: Sage Publications. 2003:219-226.
23. Golafshani N. Understanding reliability and validity in qualitative research. Qual Rep. 2003;8:597-607.
24. Maxwell JA. Understanding and validity in qualitative research. Harv Educ Rev. 1992;62:279-300.
25. Brawer MK. Hormonal therapy for prostate cancer. Rev Urol. 2006;8: S35-S47.
26. Gupta P, Sturdee DW, Hunter MS. Mid-Age Health in Women from the Indian Subcontinent (MAHWIS): general health and the experience of menopause in women. Climacteric. 2006;9:13-22. (Pubitemid 43155679)
27. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784-1788. (Pubitemid 28208931)
28. Burch PA, Loprinzi CL. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate. J Clin Oncol. 1991;17:1087-1088.
29. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059-2063. (Pubitemid 32009821)
30. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578-1583. (Pubitemid 34260538)
31. Hunter MS, Coventry S, Hamed H, Fentiman I, Grunfeld EA. Evaluation of a group cognitive behavioural intervention for women suffering from menopausal symptoms following breast cancer treatment. Psychooncology. 2009b;18:560-563.
32. Hunter MS, Mann E. A cognitive model of menopausal hot flushes. J Psychosom Res. 2010;69:491-501. doi:10.1016/j.jpsychores.2010.04.005.
33. Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients' perceptions of the side-effects of prostate cancer treatmentVa qualitative interview study. Soc Sci Med. 2006;63:911-919.
34. Oliffe J. Constructions of masculinity following prostatectomy-induced impotence. Soc Sci Med. 2005;60:2249-2259. (Pubitemid 40313370)
35. Wittmann D, Northouse L, Foley S, et al. The psychosocial aspects of sexual recovery after prostate cancer treatment. Int J Impot Res. 2009;21: 99-106.
36. Chambers SK, Schover L, Halford K, et al. ProsCan for Couples: randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer who receive radical prostatectomy. BMC Cancer. 2008;8:226-233.
37. Autorino R, Perdonà S, D'Armiento M, et al. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis. 2006;9:109-114. (Pubitemid 43970958)
38. Oliffe J. Embodied masculinity and androgen deprivation therapy. Sociol Health Illn. 2006;28:410-432. (Pubitemid 43654514)
39. Stamogiannou I, Grunfeld EA, Denison K, Muir G. Beliefs about illness and quality of life among men with erectile dysfunction. Int J Impot Res. 2005;17:142-147. (Pubitemid 40434587)
40. Wall D, Kristjanson L. Men, culture and hegemonic masculinity: understanding the experience of prostate cancer. Nurs Inq. 2005;12:87-97. (Pubitemid 40756381)
41. Gray RE, Fitch M, Phillips C, Labrecque M, Fergus K. To tell or not to tell: patterns of disclosure among men with prostate cancer. Psychooncology. 2000;9:273-282. (Pubitemid 30649354)